1 of 1
Story summary
- Roche Holding AG, the Swiss biotechnology company, aims to achieve net zero emissions by 2045.
- Roche emphasizes sustainability as a core part of its operations, focusing on medicines and diagnostics.
- The company pursues partnerships and data insights to improve healthcare delivery.
- Fenebrutinib showed clinical trial success in multiple sclerosis, supporting Roche's patient-outcome mission.
- Roche plans data submissions to regulatory authorities after additional trial results are expected in early 2026.
